At VOA, research is a key component of our mission. Over the past several years, our oncologists have participated in a number of important clinical trials, helping further scientific knowledge about cancer and bringing the latest therapies directly to patients in our community.
Clinical trial availability is critical for cancer researchers and patients alike. It is vitally important that community-based oncology centers like ours participate in furthering cancer research through clinical testing.
Because of the vast number of trials under way at any one time, there is a great need for patients who meet participation guidelines. Community-based oncology centers play a major role in identifying patients who qualify, while also extending the reach of investigational therapies.
For example, a recent review for colorectal cancer studies at www.clinicaltrials.gov showed more than 200 trials that were recruiting patients. If these trials were to be conducted in only a handful of specialized centers:
That is why it is important for community-based oncology centers such as VOA to offer patients access to clinical trials. The benefits are too far-reaching for us to ignore.
And that is why research – participating in the development and discovery of new therapies that can save lives – is a critical component of our practice’s mission.
As part of US Oncology, one of the country’s largest networks of cancer care practices and the nation’s largest integrated cancer research program, we are able to participate in many clinical trials and provide the latest, most promising drugs and treatments to patients right here in Hampton Roads.
Since 1993, more than 30,000 patients have participated in clinical trials managed by US Oncology network practices, and the network has contributed to the development of 36 cancer-fighting drugs approved for use by the Food and Drug Administration.
Throughout the last century the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.
If you are interested in learning more about our research program, please call the
VOA Research Department:
LEUKEMIA & LYMPHOMA
PHASE I TRIALS/SOLID TUMORS
Peninsula: (757) 873-9400
Southside: (757) 466-8683
USO 12-092: A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease. (A5481008)
USO 13-019: A Phase 2, Single-Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
USO 11137 - Protocol GO25632: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Bevacizumab, And Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo As First-Line Treatment Of Patients With HER2-Negative Metastatic Breast Cancer IND 113704
AZ D699BC000: A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON)
NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
USO 10-167: A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in HER2-negative Breast Cancer (MM-121-02-02-07)
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
NSABP PROTOCOL B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Amgen TRINOVA – 3 (GOG 3001): A Phase 3 Randomized, Double-Blind , Placebo-Controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
USO 11105 - Protocol CTKI258A2211: A phase II, open-label, single-arm, non-randomized, multicenter study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer
GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to primary Platinum/Taxane Chemotherapy
GOG 262: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in The Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
USO 12-177: A Pivotal Phase III Study to Evaluate Overall Survival using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia
USO 11031 - NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin versus 5-Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy (MM-398-07-03-01)
USO 12091 - BT-CL-PGG-CRC1031: Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
CALGB 80702: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo For Patients With Stage III Resected Colon Cancer
USO 08-113: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
HOG GU12-159: A Randomized Phase II Study Evaluating OGX-427 in Patients with Metastatic Castrate-Resistant Prostate Cancer Who Have PSA Progression While Receiving Abiraterone
PSMA ADC 2301: A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Castration-Resistant Metastatic Prostate Cancer (CRMPC)
EXELIXIS XL184-306: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF CABOZANTINIB (XL184) VS. MITOXANTRONE PLUS PREDNISONE IN MEN WITH PREVIOUSLY TREATED SYMPTOMATIC CASTRATION-RESISTANT PROSTATE CANCER
HOG GU10-147: Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma
USO 09-217: An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy (IMCL CP20-0902)
USO 09-187: An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (E7389-702)
LEUKEMIA & LYMPHOMA / MDS
No Active Studies
USO 13-035: A Dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology (CBKM120D2204)
USO#13012/ GO28753: A Phase II, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer after Platinum Failure
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab For Patients With Completely Resected Stage IB (> 4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)
USO 11117 - 1200.125: LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy
USO 10284: An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway (CBKM120D2201)
CTSU E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
No Active Studies
USO 12-053: A Multicenter, Open-label, Phase 1/2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone Induction Followed by Randomization to Carfilzomib Maintenance versus Observation in Newly Diagnosed Multiple Myeloma Subjects
PHASE I STUDIES/SOLID TUMORS
USO 13-053: A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
USO 11-223 (PLX108-01): A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology
USO 10-190: A Phase 1 and Pharmacologic Study of MM-111 in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors
No Active Studies
No Active Studies
No Active Studies
No Active Studies